摘要
三阴性乳腺癌(TNBC)具有特殊的流行病学及生物学特点,由于缺少特异性治疗靶点,尚无标准化疗方案,导致复发转移阶段治疗效果差,整体预后不佳。近年来,基于对肿瘤DNA同源重组修复、肿瘤免疫治疗及新型靶向药物等多方面不断研究,诸多关于晚期TNBC全身治疗的基础及临床领域已经取得一定成果,为复发转移性TNBC的精准治疗提供新的思路与方法。
Triple-negative breast cancer(TNBC) has special epidemiological and biological characteristics. Due to the lack of specific therapeutic targets, there is currently no standard chemotherapy regimen resulting in poor therapeutic response and dismal overall outcomes in the recurrence and metastasis stage. In recent years, with the continuous studies in terms of homologous recombination repair, tumor immunotherapy and new targeted drugs, certain achievements have been attained in the field of basic and clinical research concerning systemic treatment of advanced TNBC, which provide new insights for precise treatment of recurrent or metastatic TNBC.
作者
杨柳
王殊
YANG Liu;WANG Shu(Center of Breast Surgery,Peking University People’s Hospital,Beijing 100044,China)
出处
《中国普通外科杂志》
CAS
CSCD
北大核心
2019年第11期1342-1346,共5页
China Journal of General Surgery
关键词
三阴性乳腺癌
药物疗法
免疫疗法
分子靶向治疗
Triple Negative Breast Neoplasms
Drug Therapy
Immunotherapy
Molecular Targeted Therapy
